A pharmacist by training and with a PhD in Immunology from the Ludwig-Maximilians-Universität München, Kathrin brings entrepreneurial spirit and a track record in navigating therapeutic partnerships successfully to adivo. Motivated by personal experience with her dog Caesar, who fought with cancer for many years, she decided to apply her professional knowledge to solve a key problem in veterinary healthcare - the lack of species-specific immunotherapies for pets.
Prior to founding adivo in 2018, she held several positions within the R&D organization as well as the Alliance Management team at MorphoSys, a world-leading human antibody therapeutics company. The expertise gained through shepherding multiple therapeutic projects in close collaboration with international pharma partners supports adivo in establishing a leading companion animal therapeutics pipeline. At adivo, Kathrin is driving the financing and business development strategy of the company and is managing adivo’s existing alliances. Kathrin owns two dogs, Canela and Erly.